Clinical Trial Update: A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating masitinib in relapse or refractory multiple myeloma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Masitinib (masitinib)

Snippet

Sponsor: AB Science | Conditions: Multiple Myeloma | Phase 3 | Status: TERMINATED